Zhejiang Doer BioPharma Announces Global Licensing Agreement with BioNTech for Innovative Biologic Targeting Undisclosed Indication

HangzhouJuly 11, 2023PR Newswire -- Zhejiang Doer Biologics Co., Ltd. ("Doer Biologics"), a clinical-stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancer, today announced that it has entered into a licensing agreement with BioNTech SE (Nasdaq: BNTX, "BioNTech").

According to the terms of the agreement, Doer Biologics will grant BioNTech US Inc. a global license to utilize one of Doer Biologics' innovative discoveries for the research, development, manufacturing, and commercialization of novel biotherapeutics targeting an undisclosed target. Doer Biologics will receive an upfront payment as well as potential development, regulatory, and commercial milestone payments.

Dr. Huang Yanshan, founder and CEO of Doer Biologics, stated: "The licensing agreement with BioNTech is a strong testament to the tremendous potential of Doer Biologics' platform technologies, which have already been validated through extensive preclinical studies and ongoing clinical trials."

Dr. Yongliang Fang, Chief Operating Officer of Doer Biologics, commented: "We are very pleased to collaborate with BioNTech, a global leader in the biopharmaceutical industry, to translate Doer Biologics' research and development into innovative therapies. We look forward to working with BioNTech to advance this groundbreaking achievement into clinical applications and ultimately benefit patients worldwide."